Acadia Pharmaceuticals Inc. (ACAD)
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Acadia Pharmaceuticals: Remlifanserin Is In Trouble
Acadia Pharmaceuticals (ACAD) reported phase 2/3 results for remlifanserin in Alzheimer's disease psychosis, with the high dose missing statistical significance but showing positive efficacy trends. Remlifanserin's safety profile was clean, but the effect size on the primary endpoint was low, raising concerns about clinical utility and replicability in phase 3. I am now even less optimistic about remlifanserin's phase 3 success, lowering my probability of success to 25% due to efficacy and trial design concerns.
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo on the trial's main measure, but the result fell just short of statistical significance at six weeks.
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer's Psychosis Trial
ACADIA Pharmaceuticals NASDAQ: ACAD reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statistical significance on the primary endpoint but showed nominal statistical significance on a key secondary endpoint, while demonstrating a safety and tolerability profile comparable with placebo.
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
